» Articles » PMID: 30615903

Human IPSC-based Model of Severe Congenital Neutropenia Reveals Elevated UPR and DNA Damage in CD34 Cells Preceding Leukemic Transformation

Overview
Journal Exp Hematol
Specialty Hematology
Date 2019 Jan 8
PMID 30615903
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

We describe the establishment of an embryoid-body-based protocol for hematopoietic/myeloid differentiation of human induced pluripotent stem cells that allows the generation of CD34 cells or mature myeloid cells in vitro. Using this model, we were able to recapitulate the defective granulocytic differentiation in patients with severe congenital neutropenia (CN), an inherited preleukemia bone marrow failure syndrome. Importantly, in vitro maturation arrest of granulopoiesis was associated with an elevated unfolded protein response (UPR) and enhanced expression of the cell cycle inhibitor p21. Consistent with this, we found that CD34 cells of CN patients were highly susceptible to DNA damage and showed diminished DNA repair. These observations suggest that targeting the UPR pathway or inhibiting DNA damage might protect hematopoietic cells of CN patients from leukemogenic transformation, at least to some extent.

Citing Articles

Differential transcriptional control of hematopoiesis in congenital and cyclic neutropenia patients harboring mutations.

Zeidler A, Borbaran-Bravo N, Dannenmann B, Ritter M, Nasri M, Klimiankou M Haematologica. 2023; 109(5):1393-1402.

PMID: 37855057 PMC: 11063862. DOI: 10.3324/haematol.2023.284033.


Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.

Becklin K, Draper G, Madden R, Kluesner M, Koga T, Huang M CRISPR J. 2022; 5(4):517-535.

PMID: 35972367 PMC: 9529369. DOI: 10.1089/crispr.2022.0032.


Generation, expansion, and drug treatment of hematopoietic progenitor cells derived from human iPSCs.

Dannenmann B, Skokowa J STAR Protoc. 2022; 3(2):101400.

PMID: 35600931 PMC: 9117918. DOI: 10.1016/j.xpro.2022.101400.


Continuous human iPSC-macrophage mass production by suspension culture in stirred tank bioreactors.

Ackermann M, Rafiei Hashtchin A, Manstein F, Carvalho Oliveira M, Kempf H, Zweigerdt R Nat Protoc. 2022; 17(2):513-539.

PMID: 35039668 PMC: 7612500. DOI: 10.1038/s41596-021-00654-7.


Induced pluripotent stem cell models of myeloid malignancies and clonal evolution.

Reilly A, Doulatov S Stem Cell Res. 2021; 52:102195.

PMID: 33592565 PMC: 10115516. DOI: 10.1016/j.scr.2021.102195.